Telomir Pharmaceuticals climbs on promising cancer therapy data

Telomir Pharmaceuticals

07/10/2025 11:52

** Shares of drug developer Telomir Pharmaceuticals TELO.O rise 24.7% to $1.77 premarket

** Co said late on Monday its experimental drug, Telomir-1, showed promise in preclinical studies for aggressive prostate cancer, potentially helping the body fight tumor spread and resistance to treatment

** The therapy was able to restore the activity of two key tumor-suppressing genes which are often switched off in cancer cells due to abnormal DNA methylation

** Telomir added the drug worked even better when used alongside chemotherapy, showing stronger effects in reversing gene silencing

** As of last close, stock down 65% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))